media – Page 37 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

fees are stipulated for the first time, and anti-aging is not mentioned

The number of stem cell clinical research projects in China ranks second in the world. In the China Clinical Trial Registry (ChiCTR), searching with “stem cells” as the keyword, as of September 2024, it can be retrieved that more than 100 medical institutions and 738 stem cell clinical research projects have been successfully registered in ChiCTR, and 38 stem cell clinical research projects have been successfully registered in ChiCTR in 2024. China’s stem cell clinical research has entered a period of vigorous development, including the Beijing-Tianjin-Hebei region represented by Beijing, the Yangtze River Delta region represented by Shanghai, the Pearl River Delta region represented by Shenzhen, the free trade pilot zone represented by Hunan, and the “medical special zone” represented by the Hainan Boao Lecheng International Medical Tourism Pilot Zone, etc. These regional clusters are making their own efforts to actively seize the commanding heights of the biomedical industry. The ...
- Source: drugdu
- 149
- December 27, 2024
It’s 2024, why is there still no medicine for “dysmenorrhea”?

To this day, there is still no medicine for dysmenorrhea. Although in social concepts, dysmenorrhea is regarded as a common pain for women. Many women choose to endure or take painkillers to get through menstrual pain, and few people go to the doctor for this. However, dysmenorrhea is not always harmless, and this tolerance may hide great hidden dangers. Dysmenorrhea, especially severe dysmenorrhea, is likely to be a disease-endometriosis. Endometriosis is far more than just dysmenorrhea. It can not only invade surrounding tissues and other organs, causing complex symptoms, but also easily recur after treatment, and can only be relieved after menopause, bringing endless pain and torture to patients, and even called “immortal cancer”. Behind this, there are certainly many reasons. For example, wrong and rigid social concepts; for example, both patients and medical staff lack the awareness of early diagnosis and early treatment of endometriosis; most importantly, due to ...
- Source: drugdu
- 115
- December 27, 2024
CSPC AI exploded

CSPC Pharmaceutical Group has reached a blockbuster BD again. Recently, CSPC Pharmaceutical announced that it has reached a BD agreement with BeiGene on the group’s new methionine adenosyltransferase 2A (MAT2A) inhibitor, SYH2039, and will grant BeiGene the rights to develop and commercialize the pipeline globally. The BD amount this time is also very impressive: CSPC Pharmaceutical Group will receive a total of US$150 million in advance payments, and is entitled to receive up to US$135 million in potential development milestone payments and up to US$1.55 billion in potential sales milestone payments, as well as tiered sales commissions calculated based on the annual net sales of the product. It is worth mentioning that the compound was screened by CSPC Pharmaceutical through AI technology. Previously, CSPC Pharmaceutical also BD a preclinical pipeline screened by AI technology to AstraZeneca at a high price. CSPC Pharmaceutical AI exploded. ▍Why CSPC Pharmaceutical? The molecule of ...
- Source: drugdu
- 131
- December 27, 2024
Cluster development of Changchun’s pharmaceutical and health industry

Recently, the 2024 Changchun International Medical and Health Industry Expo was held in Changchun, Jilin Province. This expo attracted 648 companies to participate, with a total investment of 18.604 billion yuan in signed projects, indicating that Changchun’s pharmaceutical and health industry is gathering strong momentum. Statistics show that in the first 10 months of this year, the scale of the biopharmaceutical and life health industries in Changchun reached 92.5 billion yuan, a year-on-year increase of 10.2%. Jilin Province has abundant medicinal resources, and Changchun is located in the central part of the province, with the advantage of deep processing and utilization of high-quality authentic medicinal materials within the province. At the same time, Changchun is one of the first three biomedicine industry bases recognized by the state, gathering many scientific research institutions such as Chunguang Machinery Institute, President of Chinese Science, Changchun Yinghua Institute, 49 colleges and universities such as ...
- Source: drugdu
- 110
- December 26, 2024
Billions of yuan! Cardiovascular innovative equipment company completes Series C financing

Recently, according to the official WeChat account of Wuhan Weike Medical Technology Co., Ltd. (hereinafter referred to as Weike Medical), Weike Medical has successfully completed its Series C financing, with a financing amount of hundreds of millions of yuan, fully led by Bohua Capital, a well-known investment institution in Liangxi District, Wuxi City. It is reported that this round of financing will provide strong financial support for Weike Medical in product research and development, market expansion, and international strategic layout. According to the Yaozhi Data Investment Pattern Database, Weike Medical has successfully completed four rounds of financing in the three years from 2019 to 2021, with the highest amount being the B-round financing of hundreds of millions of RMB on December 16, 2021, promoting the research and innovation of multiple minimally invasive intervention products, accelerating the product registration and listing process, and bringing better treatment solutions to the vast number ...
- Source: drugdu
- 147
- December 26, 2024
Lianying 5T MR wins bid again, will domestic ultra-high field magnetic resonance imaging explode?

Recently, United Imaging’s first whole-body clinical ultra-high field magnetic resonance uMR Jupiter 5T was selected for the 5.0T magnetic resonance bidding project at the First Affiliated Hospital of Chongqing Medical University, winning the bid for 48 million yuan (RMB). It is worth mentioning that this is the second time that UMC uMR Jupiter 5.0T magnetic resonance imaging has won the bid after entering multiple hospitals such as Southeast University Affiliated Zhongda Hospital, Nanjing Drum Tower Hospital, Suzhou University Affiliated First Hospital, and Fudan University Affiliated Cancer Hospital in 2024. According to the data, the UMR Jupiter 5T is the world’s first 5.0T whole-body magnetic resonance imaging system for the human body. It adopts the industry’s first 5.0T ultra-high field design, redefining the clinical application scope and scientific research prospects of ultra-high field magnetic resonance imaging. At present, the United Imaging uMR Jupiter 5.0T magnetic resonance imaging has obtained NMPA, FDA, ...
- Source: drugdu
- 120
- December 26, 2024
Oncology drug competition has reached a new height

How to become the overlord in the field of oncology? In the past few years, Johnson & Johnson has taught the market a lesson in the field of myeloma. From monoclonal antibodies to CAR-T and then to bispecific antibodies, the number of treatment lines has been extended from the first line to the last line: through the progressive and broad and precise layout, Johnson & Johnson has sought a higher moat for itself and also given latecomers a smaller breakthrough gap. The growth of the overlord of multiple myeloma is in progress. At present, Johnson & Johnson’s layered handover is taking shape, and the revenue of related products in 2023 has exceeded the 10 billion US dollar mark. But such a story is destined not to belong only to Johnson & Johnson. Any powerful pharmaceutical company has its own unique core capabilities, corresponding to a smooth product portfolio echelon management ...
- Source: drugdu
- 87
- December 26, 2024
Planning a Share Swap to Absorb and Merge with Shanghai Raas

On December 22, Haier Biologics (688139) announced that the company is planning to absorb and merge with Shanghai Raas (002252) through a share swap, issuing A-shares to all shareholders of Shanghai Raas and raising matching funds through the issuance of A-shares. The company’s stock is set to be suspended from trading starting December 23 (Monday), with an expected suspension period not exceeding 10 trading days. Haier Biologics stated that during the suspension, the company will actively advance various tasks and, depending on the progress of the matter, will strictly comply with the relevant laws and regulations regarding information disclosure obligations. Once relevant matters are confirmed, the company will promptly release related announcements and apply for the resumption of trading of its stocks. Investors are encouraged to pay attention to subsequent announcements and be cautious about investment risks. On July 29, Shanghai Raas had previously announced a change in the company’s ...
- Source: drugdu
- 205
- December 26, 2024
BaiKe Biological’s Phase II Clinical Trial for Herpes Simplex Virus Type 2 mRNA Vaccine Approved

Shanghai Securities News reported on December 20 that BaiKe Biological announced in the evening that it recently received the “Clinical Trial Approval Notification” issued by the National Medical Products Administration, granting permission to conduct clinical trials for the prevention of genital herpes caused by Herpes Simplex Virus Type 2 (HSV-2) infection. The HSV-2 vaccine approved for clinical trials by the company was jointly submitted with Zhuhai Lifanda Biotechnology Co., Ltd. This vaccine is a multi-component vaccine capable of inducing both humoral immune responses and cellular immune responses, utilizing mRNA technology to further enhance the cellular immune response. Compared to traditional technology routes, it increases the likelihood of successful vaccine development. As of now, there are no related vaccine products successfully developed and marketed globally. BaiKe Biological stated that if this vaccine successfully completes its clinical trials and receives market approval, it will further enrich the company’s product pipeline, help optimize ...
- Source: drugdu
- 109
- December 26, 2024
CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine

CanSinoBio Launches Phase II/III Clinical Trials for Adsorbed Acellular DTaP Combined Vaccine Finance China News, December 20 – CanSino (688185/06185) released a voluntary disclosure announcing the official launch of Phase II/III clinical trials for its adsorbed acellular DTaP (Diphtheria, Tetanus, and Pertussis) combined vaccine (for individuals aged 6 and older), having completed enrollment of the first subject in Phase II. This vaccine aims to provide booster immunization for adolescents and adults, filling a gap in the domestic market. Currently, the vaccine has completed Phase I clinical trials, with results indicating that its immunogenicity meets expectations and that it is safe. The ongoing Phase II/III clinical trials will further assess the vaccine’s immunogenicity and safety. The company will strictly advance the clinical trials in accordance with national drug registration regulations, despite the complexity and uncertainty inherent in the vaccine development process. In the first three quarters of 2024, CanSino achieved revenue ...
- Source: drugdu
- 91
- December 26, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.